Skip to main content
Menu
US

HTRF Human & Mouse Phospho-ATG14 (Ser29) Detection Kit, 500 Assay Points

This HTRF kit enables the cell-based quantitative detection of ATG14 phosphorylation at Ser29 as a readout of the autophagy pathway.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Feature Specification
Application Cell Signaling
Sample Volume 16 µL

This HTRF kit enables the cell-based quantitative detection of ATG14 phosphorylation at Ser29 as a readout of the autophagy pathway.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Click to copy promo code to clipboard.
SAVE 15% NOW on online orders. Use promo code below.
YEAREND15
Offer valid until 12/15. Terms and conditions apply.
Product Variants
Unit Size: 500 Assay Points
Part #:
64ATG14S9PEG
List Price
USD 2,147.00
Unit Size: 10,000 Assay Points
Part #:
64ATG14S9PEH
List Price
USD 12,490.00

Overview

ATG14, Autophagy related protein 14, or BAKOR for Beclin 1-associated autophagy-related key regulator, is a key player in the autophagosome nucleation step in macroautophagy. Upon cellular stress, the nutrient/energy-sensitive sensors mTOR and AMPK lead to the activation of the ULK1 complex, which allows phosphorylation of ATG14 on Serine 29, in turn enabling the downstream activation of the PIK3C3 autophagosome nucleation complex.

Specifications

Application
Cell Signaling
Brand
HTRF
Detection Modality
HTRF
Lysis Buffer Compatibility
Lysis Buffer 1
Lysis Buffer 2
Lysis Buffer 3
Lysis Buffer 4
Molecular Modification
Phosphorylation
Product Group
Kit
Sample Volume
16 µL
Shipping Conditions
Shipped in Dry Ice
Target Class
Phosphoproteins
Target Species
Human
Mouse
Technology
TR-FRET
Unit Size
500 Assay Points

Video gallery

How it works

HTRF Phospho ATG14 assay principle

The HTRF Phospho-ATG14 (Ser29) assay measures ATG14 when phosphorylated at Ser 29. Unlike Western Blot, the assay is entirely plate-based and does not require gels, electrophoresis, or transfer. The Phospho-ATG14 (Ser29) assay uses 2 labeled antibodies: one with a donor fluorophore, the other with an acceptor. The first antibody was selected for its specific binding to the phosphorylated motif on the protein, and the second for its ability to recognize the protein independently of its phosphorylation state. Protein phosphorylation enables an immune-complex formation involving the two labeled antibodies which brings the donor fluorophore into close proximity to the acceptor, thereby generating a FRET signal. Its intensity is directly proportional to the concentration of phosphorylated protein present in the sample, and provides a means of assessing the protein’s phosphorylation state under a no-wash assay format.

1phospho-how-it-works-atg14-phospho-assay-principle.svg

 

HTRF Phospho-ATG14 Ser29 2-plate assay protocol

The 2 plate protocol involves culturing cells in a 96-well plate before lysis, then transferring lysates into a 384-well low volume detection plate before the addition of the Phospho-ATG14 Ser 29 HTRF detection reagents. This protocol enables the cells' viability and confluence to be monitored.

2phospho-how-it-works-atg14-phospho-assay-protocol-01.svg

 

HTRF Phospho-ATG14 Ser29 one-plate assay protocol

Detection of phospho ATG14 Ser 29 with HTRF reagents can be performed in a single plate used for culturing, stimulation, and lysis. No washing steps are required. This HTS-designed protocol enables miniaturization while maintaining robust HTRF quality.

3phospho-how-it-works-atg14-phospho-assay-protocol-02.svg

 

Assay validation

Validation of Phospho-ATG14 (Ser29) and Total kits on the human HCT116 cell line using ULK1/2 and mTORC1 inhibitors

Human HCT116 cells  were plated in a 96-well culture-treated plate (200,000 cells/well) in complete culture medium, and incubated overnight at 37°C, 5% CO2. The cells were treated with a dose-response of MRT68921 for 4h at 37 °C, 5% CO2. After culture medium removal, cells were then lysed with 25 µl of supplemented lysis buffer #4 (1X) for 30 min at RT under gentle shaking. After cell lysis, 14 µL of lysate were transferred into a 384-well low volume white microplate and 2 µL of Activation Buffer then 4 µL of the HTRF Phospho-ATG14 (Ser 29) or Total-ATG14 detection reagents were added. The HTRF signal was recorded after an overnight incubation at room temperature.

As expected, MRT68921, a potent and dual autophagy kinase ULK1/2 inhibitor, repressed ULK1 activation, reducing the autophagy initiation machinery and leading to a dose-dependent decrease in ATG14 phosphorylation without any effect on the expression level of the ATG14 total protein.

uman HCT116 cells  were plated in a 96-well culture-treated plate (200,000 cells/well) in complete culture medium, and incubated overnight at 37°C, 5% CO2. The cells were treated with a dose-response of AZD2014 (Vistusertib) for 4h at 37°C, 5% CO2. After culture medium removal, cells were then lysed with 25 µl of supplemented lysis buffer #4 (1X) for 30 min at RT under gentle shaking. After cell lysis, 14 µL of lysate were transferred into a 384-well low volume white microplate. 2 µL of Activation Buffer, then 4 µL of the HTRF Phospho-ATG14 (Ser 29) or Total-ATG14 detection reagents were added. The HTRF signal was recorded after an overnight incubation at room temperature.

As expected, AZD2014, a potent mTOR inhibitor, alleviated ULK1 inhibition, increasing autophagy initiation machinery, and leading to an increase in ATG14 phosphorylation on Serine 29 without any effect on the expression level of the ATG14 total protein.

4assay-validation-atg14-phospho-pharmaco-1-1.svg
5assay-validation-atg14-phospho-pharmaco-1-2.svg

 

Specificity of HTRF Phospho-ATG14 assay using knockout ATG14 HAP1 cells

Human basal phospho (Ser29) ATG14 expression level was assessed with the Phospho (Ser29) HTRF kit in HAP1 cells with both Wild Type (WT) and ATG14 knock-out (KO). Normalization was done using the GAPDH Housekeeping HTRF kit. The cell lines were cultured in flasks at 37°C, 5% CO2 and after culture medium removal, cells were then lysed with 1 mL of supplemented lysis buffer #4 (1X) per 10 million cells, for 30 min at RT under gentle shaking. After cell lysis, 14 µL of lysate were transferred into a 384-well low volume white microplate, and 2 µL of Activation Buffer, then 4 µL of the HTRF Phospho-ATG14 (Ser 29) detection reagents were added. For GAPDH, 8 µL of lysate was prediluted with 60 µL diluent before mixing 16 µL of the diluted material with 4 µL of the GAPDH detection reagents. The HTRF signal was recorded after an overnight incubation at room temperature. In HAP1 KO ATG14 cells, the HTRF signal was equivalent to the non-specific signal (not shown) indicating a complete ATG14 gene silencing and thus demonstrating the specificity of the HTRF Phospho(Ser29) ATG14 kit for the ATG14 protein. GAPDH normalization was applied to take into account slight growth differences between parental and KO cells (the phospho-ATG14 over GAPDH ratio is presented here). HAP1 ATG14 KO (1bp del) cell line from Horizon Discovery # HZGHC024663c012 HAP1 WT from Horizon Discovery # C631

6assay-validation-atg14-phospho-pharmaco-2-1.svg

 

Simplified pathway

ATG14 signaling pathway in macro-autophagy

Cellular Autophagy is a specialized degradation and recycling process that is instrumental for cell homeostasis, being activated in response to several different stresses. There are 3 types of autophagy: macroautophagy, microautophagy, and chaperone-mediated autophagy. Macroautophagy pathways involve several key steps: initiation, nucleation, elongation of phagophore complexes, then sequestration of cytoplasmic cargos with LC3-PE recruitment followed by fusion with lysosome yielding to cargo degradations.
 

Biogenesis of the autophagosome is controlled by sequential and concerted actions of the so-called autophagy related proteins, ATGs, which are activated and recruited to the ER and autophagosome membranes. The recruitment of the ULK1 complex is the first event in the initiation step. ULK1 is a Ser/Thr kinase which forms a complex with the Atg13, Atg101 and FIP200 proteins. This complex is the most upstream component of the core autophagy machinery and is therefore the key initiator of autophagy in mammalian cells. ULK1 is regulated by the key nutrient/energy-sensitive kinases mTOR and AMPK, which are both able to phosphorylate ULK1 on Serine 317 and Serine 556, and directly regulate its kinase activity.
 

The Activated ULK1 complex then binds ATG14 via ATG13, and phosphorylates ATG14 on Serine 29. The kinase activity of phosphorylated and activated ATG14 stimulates other proteins of the PIK3C3 complex (nucleation) that is responsible for the critical step of phosphorylation of phosphatidylinositols (PI) into phosphatidylinositol-3-phosphate (PI3P). This in turn is responsible for the formation of the initial phagosomal membrane structure and later allows fixation of LC3-II using other ATG proteins (ATG16/12/5 complex), thus generating a support for elongation and closing steps.
 

This means tha phosphorylation of ATG14 protein on serine 29 is a key early marker of the nucleation step in the engagement of the macroautophagic process.

7pathway-atg14.svg

 

Resources

Are you looking for resources, click on the resource type to explore further.

1-3 of 3 Resources
Brochure Icon
Brochure
HTRF assays and reagents catalog

Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...

Guide Icon
Guide
HTRF solutions, guide to major applications

This guide provides you an overview of HTRF applications in several therapeutic areas.

Whitepaper Icon
Whitepaper
Shifting the treatment paradigm: the promise of gene therapy for neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and Huntington’s, are complex disorders that affect millions...

Scroll Icon